Trials / Completed
CompletedNCT02293915
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 818 (actual)
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sodium oligo-mannurarate 900mg | sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks |
| DRUG | Placebo | simulant of sodium oligo-mannurarate capsule |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2018-06-29
- Completion
- 2018-09-28
- First posted
- 2014-11-19
- Last updated
- 2018-10-10
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02293915. Inclusion in this directory is not an endorsement.